Science-advisor
REGISTER info/FAQ
Login
username
password
     
forgot password?
register here
 
Research articles
  search articles
  reviews guidelines
  reviews
  articles index
My Pages
my alerts
  my messages
  my reviews
  my favorites
 
 
Stat
Members: 3643
Articles: 2'487'895
Articles rated: 2609

28 March 2024
 
  » pubmed » pmid12068308

 Article overview


Mutations of the BRAF gene in human cancer
Helen Davies ; Graham R Bignell ; Charles Cox ; Philip Stephens ; Sarah Edkins ; Sheila Clegg ; Jon Teague ; Hayley Woffendin ; Mathew J Garnett ; William Bottomley ; Neil Davis ; Ed Dicks ; Rebecca Ewing ; Yvonne Floyd ; Kristian Gray ; Sarah Hall ; Rachel Hawes ; Jaime Hughes ; Vivian Kosmidou ; Andrew Menzies ; Catherine Mould ; Adrian Parker ; Claire Stevens ; Stephen Watt ; Steven Hooper ; Rebecca Wilson ; Hiran Jayatilake ; Barry A Gusterson ; Colin Cooper ; Janet Shipley ; Darren Hargrave ; Katherine Pritchard-Jones ; Norman Maitl ; Georgia Chenevix-Trench ; Gregory J Riggins ; Darell D Bigner ; Giuseppe Palmieri ; Antonio Cossu ; Adrienne Flanagan ; Andrew Nicholson ; Judy W C Ho ; Suet Y Leung ; Siu T Yuen ; Barbara L Weber ; Hilliard F Seigler ; Timothy L Darrow ; Hugh Paterson ; Richard Marais ; Christopher J Marshall ; Richard Wooster ; Michael R Stratton ; P Andrew Futreal ;
Date 27 Jun 2002
Journal Nature, 417 (6892), 949-54
AbstractCancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis signalling pathways in which at least one gene is mutated in human cancer. The RAS RAF MEK ERK MAP kinase pathway mediates cellular responses to growth signals. RAS is mutated to an oncogenic form in about 15% of human cancer. The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS. Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers. All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%. Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells. Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation. As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.
Source PubMed, pmid12068308 doi: 10.1038/nature00766
Services Forum | Review | Favorites   
 
Visitor rating: did you like this article? no 1   2   3   4   5   yes

No review found.
 Did you like this article?

This article or document is ...
important:
of broad interest:
readable:
new:
correct:
Global appreciation:

  Note: answers to reviews or questions about the article must be posted in the forum section.
Authors are not allowed to review their own article. They can use the forum section.

browser claudebot






ScienXe.org
» my Online CV
» Free


News, job offers and information for researchers and scientists:
home  |  contact  |  terms of use  |  sitemap
Copyright © 2005-2024 - Scimetrica